Femasys (NASDAQ:FEMY) Stock Bumped Down to “Strong Sell” by Wall Street Zen

Wall Street Zen lowered shares of Femasys (NASDAQ:FEMY) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the company. Weiss Ratings cut Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Maxim Group cut their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Lake Street Capital cut their price target on shares of Femasys to $10.00 and set a “buy” rating on the stock in a report on Tuesday, August 18th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Femasys Trading Down 2.4%

NASDAQ:FEMY opened at $2.05 on Friday. The stock has a market cap of $17.18 million, a price-to-earnings ratio of -0.58 and a beta of -2.16. Femasys has a one year low of $1.96 and a one year high of $22.20. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.55 and a current ratio of 2.14. The business’s 50-day simple moving average is $2.69 and its 200 day simple moving average is $5.34.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.73 million.

Insider Activity at Femasys

In other news, CEO Kathy Lee-Sepsick bought 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The shares were bought at an average price of $3.20 per share, with a total value of $50,000.00. Following the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Dov Elefant bought 15,625 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was purchased at an average price of $3.20 per share, with a total value of $50,000.00. Following the transaction, the chief financial officer owned 15,625 shares in the company, valued at approximately $50,000. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 38,750 shares of company stock worth $124,000 in the last 90 days. 7.75% of the stock is currently owned by insiders.

Femasys Company Profile

Femasys Inc is a women’s health company focused on developing and commercializing minimally invasive technologies for reproductive health and fertility care. The company’s products are designed to provide non-surgical or less invasive alternatives for contraception, diagnostic procedures and treatments involving the female reproductive system.

Femasys’ lead product candidate is FemBloc, an investigational, non-surgical permanent birth-control system intended to prevent pregnancy by blocking the fallopian tubes.